Adlai Nortye Ltd. American Depositary Shares Asset Resilience Ratio

Latest as of December 2025: 0.00%

Adlai Nortye Ltd. American Depositary Shares asset resilience ratio. Adlai Nortye Ltd. American Depositary Shares (ANL) has an Asset Resilience Ratio of 0.00% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ANL cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Liquid Assets

$0.00
Cash + Short-term Investments

Total Assets

$34.43 Million
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Adlai Nortye Ltd. American Depositary Shares (2020–2025)

Asset resilience ratio of Adlai Nortye Ltd. American Depositary Shares from 2020 to 2025. This chart shows how Adlai Nortye Ltd. American Depositary Shares's Asset Resilience Ratio has changed over time. Read ANL liabilities breakdown for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Adlai Nortye Ltd. American Depositary Shares's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Adlai Nortye Ltd. American Depositary Sh assets under control.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $0.00 0%
Total Liquid Assets $0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Adlai Nortye Ltd. American Depositary Shares maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Adlai Nortye Ltd. American Depositary Shares Industry Peers by Asset Resilience Ratio

Compare Adlai Nortye Ltd. American Depositary Shares's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
HLB Co. Ltd
KQ:028300
Biotechnology 3.29%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Shanghai Medicilon Inc
SHG:688202
Biotechnology 6.69%
Blue Jet Healthcare Limited
NSE:BLUEJET
Biotechnology 13.81%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.76%
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
Biotechnology 5.52%

Adlai Nortye Ltd. American Depositary Shares Asset Resilience Ratio by Year (2020–2025)

Adlai Nortye Ltd. American Depositary Shares asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Adlai Nortye Ltd. American Depositary Shares.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.00% $0.00 $34.43 Million --
2024-12-31 0.01% $7.00K $71.27 Million -5.37pp
2023-12-31 5.38% $7.01 Million $130.19 Million -23.94pp
2022-12-31 29.32% $21.29 Million $72.59 Million -11.54pp
2021-12-31 40.86% $53.81 Million $131.69 Million +40.21pp
2020-12-31 0.66% $241.00K $36.74 Million --
pp = percentage points

About Adlai Nortye Ltd. American Depositary Shares

NASDAQ:ANL USA Biotechnology
Market Cap
$560.92 Million
Market Cap Rank
#11269 Global
#2946 in USA
Share Price
$9.55
Change (1 day)
-7.10%
52-Week Range
$0.88 - $16.60
All Time High
$16.60
About

Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rect… Read more